Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-analysis.
Associations between ghrelin and ghrelin receptor polymorphisms and cancer in Caucasian populations: a meta-analysis.
复制标题
DOI：
10.1186/s12863-014-0118-3
复制
发表时间：
2014-11-07
期刊：
影响因子：
2.9
通讯作者：
Chopin LK
中科院分区：
文献类型：
--
作者：
Pabalan NA;Seim I;Jarjanazi H;Chopin LK
越来越多的证据表明，胃饥饿素轴，包括胃饥饿素（GHRL）及其受体，生长激素促分泌受体（GHSR），在癌症进展中发挥作用。据报道，胃饥饿素基因和胃饥饿素受体基因多态性对癌症有一系列影响，从增加风险到预防癌症，或者没有关联。在这项研究中，我们旨在通过对已发表的病例对照研究进行荟萃分析，阐明胃饥饿素和胃饥饿素受体多态性在癌症中的作用。我们使用PubMed搜索引擎对MEDLINE中截至2013年1月发表的文献进行了检索。研究人员对来自全高加索人群的6项病例对照研究的8430例病例和14008例对照进行了个体数据评估，以确定乳腺癌、食管癌、结直肠癌和非霍奇金淋巴瘤患者的3种胃饥饿素基因（GHRL; rs696217、rs4684677、rs2075356）和1种胃饥饿素受体（GHSR; rss572169）多态性。在整体分析中，纯合和隐性关联表明，rs696217和rs2075356 GHRL多态性的小等位基因可降低癌症风险（优势比[OR] 0.61-0.78）。单独分析时，乳腺癌患者的风险没有变化（OR为0.73-0.83）。相比之下，rs4684677 GHRL和rss572169 GHSR多态性会增加乳腺癌风险（OR分别为1.97-1.98,p = 0.08和OR为1.42-1.43,p = 0.08）。除共显性效应rs572169外，所有显性效应和共显性效应均为零效应（OR为0.96-1.05），伴有临界风险增加（OR为1.08,p = 0.05）。本研究提示，rs696217和rs2075356 ghrelin基因（GHRL）多态性可能保护携带者预防乳腺癌，rs4684677 GHRL和rss572169 GHSR多态性可能增加携带者患乳腺癌的风险。此外，还需要更大规模的研究来证实这些发现。
There is growing evidence that the ghrelin axis, including ghrelin (GHRL) and its receptor, the growth hormone secretagogue receptor (GHSR), play a role in cancer progression. Ghrelin gene and ghrelin receptor gene polymorphisms have been reported to have a range of effects in cancer, from increased risk, to protection from cancer, or having no association. In this study we aimed to clarify the role of ghrelin and ghrelin receptor polymorphisms in cancer by performing a meta-analysis of published case–control studies. We conducted searches of the literature published up to January 2013 in MEDLINE using the PubMed search engine. Individual data on 8,430 cases and 14,008 controls from six case–control studies of an all Caucasian population were evaluated for three ghrelin gene (GHRL; rs696217, rs4684677, rs2075356) and one ghrelin receptor (GHSR; rs572169) polymorphism in breast cancer, esophageal cancer, colorectal cancer and non-Hodgkins lymphoma. In the overall analysis, homozygous and recessive associations indicated that the minor alleles of rs696217 and rs2075356 GHRL polymorphisms conferred reduced cancer risk (odds ratio [OR] 0.61-0.78). The risk was unchanged for breast cancer patients when analysed separately (OR 0.73-0.83). In contrast, the rs4684677 GHRL and the rs572169 GHSR polymorphisms conferred increased breast cancer risk (OR 1.97-1.98, p = 0.08 and OR 1.42-1.43, p = 0.08, respectively). All dominant and co-dominant effects showed null effects (OR 0.96-1.05), except for the rs572169 co-dominant effect, with borderline increased risk (OR 1.08, p = 0.05). This study suggests that the rs696217 and rs2075356 ghrelin gene (GHRL) polymorphisms may protect carriers against breast cancer, and the rs4684677 GHRL and rs572169 GHSR polymorphisms may increase the risk among carriers. In addition, larger studies are required to confirm these findings.
登录
查看更多内容
影响因子：
1.7
作者：
Crisà, A;Marchitelli, C;Valentini, A
通讯作者：
Valentini, A
影响因子：
4.3
作者：
Deng, Bing;Wen, Jianghui;Jiang, Siwen
通讯作者：
Jiang, Siwen
影响因子：
1.8
作者：
Guimaraes, Simone E. F.;Stahl, Chad H.;Rothschild, Max F.
通讯作者：
Rothschild, Max F.
影响因子：
2.5
作者：
Marchitelli, C;Savarese, MC;Valentini, A
通讯作者：
Valentini, A
影响因子：
4.5
作者：
Mosher DS;Quignon P;Bustamante CD;Sutter NB;Mellersh CS;Parker HG;Ostrander EA
通讯作者：
Ostrander EA